TICKERNERD
Menu
MGXMGXHealthcare · Biotechnology

MGX Stock Forecast: Metagenomi Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.23
+2.50% on the day

The 5 Wall Street analysts covering Metagenomi Therapeutics, Inc. hold a median 12-month price target of $7 — +469.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$46.5M
Ticker Nerd rank
28 / 100
Median analyst target
$7.00
Analysts covering
5
Total return, dividends reinvested
1W
0.0%
1M
+0.8%
YTD
−24.1%
1Y
−33.5%
From 52W high
−63.3%
From 52W low
+7.9%
$1.14
$3.35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MGX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Metagenomi Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
85
Size
83
Accruals
71
Quality
40
Volatility
31
Momentum
26
Revisions
26
Growth
18
Value
10

Issuance (85): The share count has been shrinking and the company is not leaning on new borrowing.

Value (10): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MGX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26MGXHigh $9.00Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $5.00Median $7.00High $9.00

The green dot is the last close — the median target sits +469.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026Wells FargoMaintainsOverweight$9.00 → $7.00
7 July 2026Chardan CapitalMaintainsBuy$7.00 → $5.00
7 July 2026Chardan CapitalMaintainsBuy—
12 May 2026Wells FargoMaintainsOverweight—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025Chardan CapitalMaintainsBuy—
14 Aug 2025Wells FargoMaintainsOverweight—
15 May 2025Chardan CapitalMaintainsBuy—
14 May 2025Wells FargoMaintainsOverweight—
3 Apr 2025HC Wainwright & Co.MaintainsBuy—
18 Mar 2025Wells FargoMaintainsOverweight—
10 Dec 2024HC Wainwright & Co.MaintainsBuy—
21 Nov 2024HC Wainwright & Co.ReiteratesBuy—
20 Nov 2024Chardan CapitalMaintainsBuy—
15 Oct 2024HC Wainwright & Co.ReiteratesBuy—
6 Sept 2024HC Wainwright & Co.ReiteratesBuy—
5 Sept 2024Chardan CapitalMaintainsBuy—
21 Aug 2024HC Wainwright & Co.MaintainsBuy—
19 Aug 2024Chardan CapitalMaintainsBuy—
15 Aug 2024BMO CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MGX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Metagenomi Therapeutics, Inc. (MGX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.5×

Cheaper than 80% of US stocks

Price / sales
3.4×

Cheaper than 37% of US stocks

Price / book
0.4×

Cheaper than 87% of US stocks

EV / EBITDA
0.4×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
−68.1%

Higher than 3% of US stocks

Earnings growth (YoY)
−69.8%

Higher than 6% of US stocks

Gross margin
—
Operating margin
11195.7%

Higher than 99% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−60.6%

Higher than 19% of US stocks

Return on assets
−28.2%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MGX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MGXMetagenomi Therapeutics, Inc.$46.5M
28
CNTXContext Therapeutics, Inc.$45.9M
31
FLNAFilana Therapeutics, Inc.$46.4M
58
VERUVeru, Inc.$45.0M
40
HYPDHyperion DeFi, Inc.$48.2M
30
KPTIKaryopharm Therapeutics, Inc.$44.2M
65
RNAZTransCode Therapeutics, Inc.$48.6M
23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Metagenomi Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MGX news & analysis

Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 10 Aug 2026negative

Metagenomi Therapeutics reported a quarterly loss of $0.73 per share for Q2, which was wider than the Zacks Consensus Estimate of a $0.63 loss. This compares with a loss of $0.54 per share in the same period a year ago, meaning its revenue fell short of estimates.

Why it matters — MGX watchers would care because the company posted a larger-than-expected quarterly loss and missed revenue estimates, indicating weaker-than-anticipated financial performance for the period.

FAQ

Frequently asked questions about MGX stock

What is the MGX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Metagenomi Therapeutics, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MGX stock a buy right now?

Of the 5 analysts covering Metagenomi Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Metagenomi Therapeutics, Inc. 28 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MGX?

As at 22 Aug 2026, Metagenomi Therapeutics, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (85 of 100).

Will MGX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +469.1% from the last close, and Ticker Nerd's factor model ranks Metagenomi Therapeutics, Inc. 28 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MGX stock forecast for 2030?

No analyst covering Metagenomi Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $9 over the next 12 months.

How has MGX stock performed over the past year?

Metagenomi Therapeutics, Inc. returned -33.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Metagenomi Therapeutics, Inc. do?

Metagenomi Inc. is a biotechnology company at the forefront of developing advanced gene editing technologies.

What is the latest news on MGX?

The most recent item we track (Zacks Investment Research, 10 Aug 2026): "Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates". Metagenomi Therapeutics reported a quarterly loss of $0.73 per share for Q2, which was wider than the Zacks Consensus Estimate of a $0.63 loss. This compares with a loss of $0.54 per share in the same period a year ago, meaning its revenue fell short of estimates.

Company

About Metagenomi Therapeutics, Inc.

Metagenomi Inc. is a biotechnology company at the forefront of developing advanced gene editing technologies. The primary function of the company is to enable precise and efficient genetic modifications through its proprietary platform, which harnesses naturally occurring enzymes. This offers broad applications across multiple sectors, notably in healthcare, agriculture, and industrial biotechnology. Through its innovative approach, Metagenomi aims to address genetic disorders, improve crop resilience, and enhance bio-based manufacturing processes. In the financial market, Metagenomi Inc. represents a pivotal entity within the biotech industry, driven by the increasing demand for gene editing solutions to tackle complex biological challenges. Its role is significant as it contributes to cutting-edge therapies and sustainable solutions, making it a key player in shaping the future of biotechnology.

CEO Dr. Jian Irish M.B.A., Ph.D. · 113 employees · United States · https://metagenomi.co